Please login to the form below

Not currently logged in
Email:
Password:

European firms face compliance challenges

The European Trends in Aggregate Spend, Transparency and Disclosure report reveals life science concerns over the compliance landscape

Results of a survey into European trends in aggregate spend, transparency and disclosure, issued on November 16 by Cegedim Relationship Management, reveal that 93 per cent of respondents are concerned that regulatory compliance will be a major challenge to the life sciences industry in Europe over the next three years, and impact industry image.

Survey respondents, comprising a representative sample of European executives from compliance, legal, marketing and sales departments within life science organisations, cited data identification, consistency and quality as major challenges to project implementation and compliance governance processes. 

While the European compliance function has traditionally focused on high-level governance design, the survey predicts changes to the evolving compliance landscape will have an effect on daily processes. For instance, the research predicts a 10 per cent drop in the use of Excel to monitor expenditure, and an increased dependency on third party solutions to meet compliance requirements.

Regulatory compliance is top of the agenda across Europe, but is particularly so in the UK, where the industry body - the Association of the British Pharmaceutical Industry (ABPI)  – is implementing transparency reforms to its Code and amendments to the Bribery Act will be legislated in April 2010.

17th November 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics